GREENWICH LIFESCIENCES, INC. Operating Expenses
GREENWICH LIFESCIENCES, INC. (GLSI) reported Operating Expenses of $4.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. operating expenses for the quarter ending 2026-06-30 was $4.02M, a 6.69% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. operating expenses for the quarter ending 2026-03-31 was $5.73M, a 106.80% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. operating expenses for the quarter ending 2025-12-31 was $9.18M, a 5.50% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. operating expenses for the quarter ending 2025-09-30 was $3.73M, a 36.83% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. operating expenses for fiscal 2025 was $19.45M, a 10.27% increase from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. operating expenses for fiscal 2024 was $17.64M, a 89.08% increase from fiscal 2023.
- GREENWICH LIFESCIENCES, INC. operating expenses for fiscal 2023 was $9.33M, a 16.01% increase from fiscal 2022.
- GREENWICH LIFESCIENCES, INC. operating expenses for fiscal 2022 was $8.04M, a 74.87% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.02M 10-Q · filed 2026-08-11 | $9.75M 10-Q · filed 2026-08-11 | $18.92M derived: sum of 3 quarters · filed 2026-08-11 | $22.66M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $5.73M 10-Q · filed 2026-06-04 | $14.90M derived: sum of 2 quarters · filed 2026-06-04 | $18.64M derived: sum of 3 quarters · filed 2026-06-04 | $22.40M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $9.18M derived: 10-K 12 month − 10-K 9 month · filed 2026-06-01 | $12.91M derived: sum of 2 quarters · filed 2026-06-01 | $16.68M derived: sum of 3 quarters · filed 2026-08-11 | $19.45M 10-K · filed 2026-06-01 | ||||
| 2025-09-30 | $3.73M 10-K · filed 2026-06-01 | $4.17M 10-Q · filed 2025-11-14 | $7.50M derived: sum of 2 quarters · filed 2026-08-11 | $10.27M 10-K · filed 2026-06-01 | $11.50M 10-Q · filed 2025-11-14 | $19.98M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $3.77M 10-Q · filed 2026-08-11 | $4.05M 10-Q · filed 2025-08-14 | $6.54M 10-Q · filed 2026-08-11 | $7.33M 10-Q · filed 2025-08-14 | $16.25M derived: sum of 3 quarters · filed 2026-08-11 | $18.98M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $2.77M 10-Q · filed 2026-06-04 | $3.28M 10-Q · filed 2025-05-20 | $12.48M derived: sum of 2 quarters · filed 2026-06-04 | $15.21M derived: sum of 3 quarters · filed 2026-06-04 | $17.87M derived: sum of 4 quarters · filed 2026-06-04 | |||
| 2024-12-31 | $9.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $12.44M derived: sum of 2 quarters · filed 2026-06-01 | $15.10M derived: sum of 3 quarters · filed 2026-06-01 | $17.64M 10-K · filed 2026-06-01 | $16.01M 10-K · filed 2025-04-15 | |||
| 2024-09-30 | $2.73M 10-Q · filed 2025-11-14 | $5.39M derived: sum of 2 quarters · filed 2025-11-14 | $7.93M 10-Q · filed 2025-11-14 | $10.76M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $2.66M 10-Q · filed 2025-08-14 | $5.20M 10-Q · filed 2025-08-14 | $8.03M derived: sum of 3 quarters · filed 2025-08-14 | $10.54M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $2.54M 10-Q · filed 2025-05-20 | $5.37M derived: sum of 2 quarters · filed 2025-05-20 | $7.88M derived: sum of 3 quarters · filed 2025-05-20 | $9.62M derived: sum of 4 quarters · filed 2025-05-20 | ||||
| 2023-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $5.34M derived: sum of 2 quarters · filed 2025-04-15 | $7.09M derived: sum of 3 quarters · filed 2025-04-15 | $9.33M 10-K · filed 2025-04-15 | ||||
| 2023-09-30 | $2.50M 10-Q · filed 2024-11-14 | $4.25M derived: sum of 2 quarters · filed 2024-11-14 | $6.49M 10-Q · filed 2024-11-14 | $9.39M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $1.75M 10-Q · filed 2024-08-14 | $3.99M 10-Q · filed 2024-08-14 | $6.88M derived: sum of 3 quarters · filed 2024-08-14 | $9.27M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $2.24M 10-Q · filed 2024-05-20 | $5.14M derived: sum of 2 quarters · filed 2024-05-20 | $7.52M derived: sum of 3 quarters · filed 2024-05-20 | $8.29M derived: sum of 4 quarters · filed 2024-05-20 | ||||
| 2022-12-31 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $5.28M derived: sum of 2 quarters · filed 2024-04-15 | $6.05M derived: sum of 3 quarters · filed 2024-04-15 | $8.04M 10-K · filed 2024-04-15 | ||||
| 2022-09-30 | $2.38M 10-Q · filed 2023-10-19 | $3.16M derived: sum of 2 quarters · filed 2023-10-19 | $5.15M 10-Q · filed 2023-10-19 | $7.52M derived: sum of 4 quarters · filed 2023-10-19 | ||||
| 2022-06-30 | $773.31K 10-Q · filed 2023-08-21 | $2.76M 10-Q · filed 2023-08-21 | $5.14M derived: sum of 3 quarters · filed 2023-08-21 | $6.01M derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | $1.99M 10-Q · filed 2023-05-22 | $4.37M derived: sum of 2 quarters · filed 2023-05-22 | $5.23M derived: sum of 3 quarters · filed 2023-05-22 | $5.99M derived: sum of 4 quarters · filed 2023-05-22 | ||||
| 2021-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.24M derived: sum of 2 quarters · filed 2023-03-31 | $4.00M derived: sum of 3 quarters · filed 2023-03-31 | $4.60M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $866.69K 10-Q · filed 2022-11-14 | $1.62M derived: sum of 2 quarters · filed 2022-11-14 | $2.22M 10-Q · filed 2022-11-14 | $3.37M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $753.45K 10-Q · filed 2022-08-15 | $1.35M 10-Q · filed 2022-08-15 | $2.51M derived: sum of 3 quarters · filed 2022-08-15 | $2.76M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $600.61K 10-Q · filed 2022-05-20 | $1.75M derived: sum of 2 quarters · filed 2022-05-20 | $2.01M derived: sum of 3 quarters · filed 2022-05-20 | $2.22M derived: sum of 4 quarters · filed 2022-05-20 | ||||
| 2020-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.41M derived: sum of 2 quarters · filed 2022-03-21 | $1.62M derived: sum of 3 quarters · filed 2022-03-21 | $1.86M 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | $256.87K 10-Q · filed 2021-11-15 | $467.30K derived: sum of 2 quarters · filed 2021-11-15 | $711.94K 10-Q · filed 2021-11-15 | $1.05M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $210.43K 10-Q · filed 2021-08-13 | $455.07K 10-Q · filed 2021-08-13 | $791.61K derived: sum of 3 quarters · filed 2021-08-13 | $1.13M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $244.64K 10-Q · filed 2021-05-20 | $581.18K derived: sum of 2 quarters · filed 2021-05-20 | $917.19K derived: sum of 3 quarters · filed 2021-05-20 | |||||
| 2019-12-31 | $336.54K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $672.55K derived: sum of 2 quarters · filed 2021-03-31 | $3.43M 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $336.01K 10-Q · filed 2020-11-16 | $3.09M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |